SSY Group wins China NMPA approval for ozagrel sodium injection

PUBT · 2d ago
SSY Group wins China NMPA approval for ozagrel sodium injection
  • SSY Group secured China NMPA production registration approval for ozagrel sodium injection in 5 ml:40 mg, 2.5 ml:20 mg.
  • Classified as Category 3 chemical drug, deemed to have passed generic consistency evaluation.
  • Approval expands ozagrel sodium coverage to small-volume injection, complementing existing sodium chloride infusion products to target neurology demand.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SSY Group Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260825-12297724), on August 25, 2026, and is solely responsible for the information contained therein.